Nuvelution, which is aiming to bring a collaborative element to drug development, has raised an undisclosed amount in a Novo-backed series A round.
US-based research and development services startup Nuvelution Pharma raised an undisclosed amount from investors including pharmaceutical company Novo and venture capital firm Clarus Ventures yesterday.
Nuvelution will provide research and development services to the pharmaceutical and biotechnology industries, offering a collaborative, risk-sharing approach to late-stage clinical development.
The company will seek to harness between $50m and $500m in investment for these collaborations, and the series A round will support its initial operations.
Martin Edwards and Thomas Dyrberg, senior partners at…
